Panacea Biotech Q1 net loss at Rs 60.92 crore
Panacea Biotech Ltd today reported net loss of Rs 60.92 crore for the first quarter ended June 30, 2013.
By PTI | Updated:
NEW DELHI: Panacea Biotech Ltd today reported net loss of Rs 60.92 crore for the first quarter ended June 30, 2013.
The company had reported net loss of Rs 65.97 crore in the April-June quarter of the last fiscal.
Panacea Biotech's net sales in Q1, 2013-14 were at Rs 104.46 crore, an increase of 25.70 per cent as against Rs 83.10 crore in the year-ago period, the company said in BSE filing.
Revenue from vaccines in Q1 grew over four fold at Rs 28.04 crore, and revenue from formulations was at Rs 81.58 crore down 0.22 per cent.
Overall expenses in the quarter were at Rs 145.72 crore, an increase of 14.43 per cent compared with Rs 127.34 crore in the corresponding period last year.
Panacea Biotech scrip closed at Rs 94.50, up 3 per cent, on the BSE.
The company had reported net loss of Rs 65.97 crore in the April-June quarter of the last fiscal.
Panacea Biotech's net sales in Q1, 2013-14 were at Rs 104.46 crore, an increase of 25.70 per cent as against Rs 83.10 crore in the year-ago period, the company said in BSE filing.
Revenue from vaccines in Q1 grew over four fold at Rs 28.04 crore, and revenue from formulations was at Rs 81.58 crore down 0.22 per cent.
Overall expenses in the quarter were at Rs 145.72 crore, an increase of 14.43 per cent compared with Rs 127.34 crore in the corresponding period last year.
Panacea Biotech scrip closed at Rs 94.50, up 3 per cent, on the BSE.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
